We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma.
- Authors
Sapienza, Maria Rosaria; Fuligni, Fabio; Melle, Federica; Tabanelli, Valentina; Indio, Valentina; Laginestra, Maria Antonella; Motta, Giovanna; Mazzara, Saveria; Cerroni, Lorenzo; Pileri, Alessandro; Facchetti, Fabio; Paulli, Marco; Cascione, Luciano; Laganà, Alessandro; Berti, Emilio; Ferracin, Manuela; Agostinelli, Claudio; Sabattini, Elena; Croce, Carlo Maria; Pileri, Stefano Aldo
- Abstract
Keywords: BPDCN; discriminant analysis; miRNAs; MS EN BPDCN discriminant analysis miRNAs MS 831 833 3 12/31/20 20201201 NES 201201 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and myeloid sarcoma (MS) are two rare hematological neoplasms, both stemming from a myeloid precursor undergoing divergent malignant transformation.1 They can primarily present in the skin, with or without extramedullary organ involvement and leukemic dissemination, and are characterized by a highly aggressive clinical course with dismal prognosis (overall survival 12-14 months).1 Possibly due to their rareness, BPDCN and MS still show unexplored biological facets and lack a standardized therapeutic approach, thus justifying their inclusion among orphan tumors. To evaluate the impact of these differentially expressed miRNAs on the BPDCN transcriptional program and determine miRNA-genes regulatory pathways potentially contributing to BPDCN pathogenesis, we performed a functional network analysis. Interestingly, we found that in BPDCN respect to MS the I TP53 i signaling may be inhibited by miRNAs upregulated while the dysregulation of the intrinsic apoptotic pathway may be due to lower miRNAs expression level.
- Subjects
DENDRITIC cells; MICRORNA; SARCOMA; TUMORS
- Publication
Hematological Oncology, 2020, Vol 38, Issue 5, p831
- ISSN
0278-0232
- Publication type
letter
- DOI
10.1002/hon.2782